id
stringlengths 14
14
| page_content
stringlengths 10
2.06k
| source
stringclasses 1
value |
|---|---|---|
c1049761fc1c-0 | Index 947
prevalence of, 625
risk and prognostic factors for, 626–627
specifiers for, 625
neurodevelopmental disorders and, 38, 39, 44,
73
psychotic disorders and, 99, 117
severity ratings for, 625, 626
trauma- and stressor-related disorders and,
280, 281, 284, 286
Tremor, medication-induced, 712
Trichotillomania (hair-pulling disorder), 235, 236,
251–254
associated features supporting diagnosis of,
252
comorbidity with, 254
culture-related diagnostic issues in, 253
development and course of, 253
diagnostic criteria for, 251
diagnostic features of, 251–252
diagnostic markers for, 253
differential diagnosis of, 253–254
functional consequences of, 253
prevalence of, 252
risk and prognostic factors for, 253
Trúng gió, 211, 212
Unspecified mental disorder, 15–16, 19–20, 708
due to another medical condition, 708
Vascular neurocognitive disorder, major or mild,
591, 603, 621–624
associated features supporting diagnosis of,
622
comorbidity with, 624
development and course of, 623
diagnostic criteria for, 621
diagnostic features of, 621–622
diagnostic markers for, 623
differential diagnosis of, 623–624
functional consequences of, 623
prevalence of, 622–623
risk and prognostic factors for, 623Voyeuristic disorder, 685, 686–688
comorbidity with, 688 | dsm5.pdf |
c1049761fc1c-1 | comorbidity with, 688
development and course of, 688
diagnostic criteria for, 686–687
diagnostic features of, 687
differential diagnosis of, 688
gender-related diagnostic issues in, 688
prevalence of, 687–688
risk and prognostic factors for, 688
specifiers for, 687
Withdrawal from substance, 481, 485–487
alcohol, 499–501
caffeine, 506–508
cannabis, 517–519
delirium due to, 598
development and course of, 487
duration of effects and, 486
laboratory findings associated with, 486–487
multiple substances, 486
opioids, 484, 547–549
other (or unknown) substance, 583–584
recording procedures for, 487
related to route of administration and speed of
substance effects, 486
sedative, hypnotic, or anxiolytic, 484, 557–560
stimulant, 484, 569–570
tobacco, 484, 575–576
World Health Organization (WHO), 6, 23
International Classification of Diseases (ICD), 21
revision process for ICD-11, 6, 10, 11–12
use of ICD-9-CM and ICD-10 codes, 12, 16,
22, 23, 29
International Classification of Functioning,
Disability and Health (ICF), 21, 734
World Health Organization Disability Assessment
Schedule 2.0 (WHODAS), 16, 21, 734,
745–748
additional scoring and interpretation guidance
for DSM-5 users, 745–746 | dsm5.pdf |
c1049761fc1c-2 | additional scoring and interpretation guidance
for DSM-5 users, 745–746
frequency of use of, 746
scoring instructions provided by WHO for, 745 | dsm5.pdf |